TABLE 1

Solute carriers associated with cellular accumulation of platinum chemotherapeutics

Drug [Alias]	Mechanism of Action	Principle Side Effects	Transporters	References
Carboplatin [Paraplatin]	Platination; DNA cross-linking	Nausea and vomiting	SLC28A1 (CTR1)^{^a}	(Larson et al., 2009)
		Myelosuppression
		Neurotoxicity
		Electrolyte abnormalities
		Hypersensitivity reaction
Cisplatin [Platinol]	Platination; DNA cross-linking	Nausea and vomiting	SLC22A1 (OCT1)^{^a}^,^{^b} SLC22A2 (OCT2)^{^a}^,^{^b}^,^{^c} SLC31A1 (CTR1)^{^a}^,^{^b} SLC47A1 (MATE1)^{^a}^,^{^b}	(Yokoo et al., 2007; Filipski et al., 2009; Larson et al., 2009; Tanihara et al., 2009; Nakamura et al., 2010)
		Myelosuppression
		Neurotoxicity
		Electrolyte abnormalities
		Hypersensitivity reaction
		Renal toxicity
		Ototoxicity
Oxaliplatin [Eloxatin]	Platination; DNA cross-linking	Nausea and vomiting	SLC22A1 (OCT1)^{^a}SLC22A2 (OCT2)^{^a}^,^{^b} SLC22A3 (OCT3)^{^a} SLC22A4 (OCTN1)^{^a} SLC22A5 (OCTN2)^{^a} SLC31A1 (CTR1)^{^a} SLC47A1 (MATE1)^{^a} SLC47A2 (MATE2-K)^{^a}	(Yonezawa et al., 2006; Yokoo et al., 2007; Larson et al., 2009; Burger et al., 2010; Sprowl et al., 2013a)
		Myelosuppression
		Neurotoxicity
		Hypersensitivity reaction
		Diarrhea

↵^a Evidence of drug uptake being regulated by solute carriers in vitro.
↵^b Evidence of drug uptake being regulated by solute carriers in vivo.
↵^c Evidence of drug uptake being regulated by solute carriers in patient populations.